Kinnate Biopharma (KNTE): Price and Financial Metrics
GET POWR RATINGS... FREE!
KNTE Stock Price Chart Interactive Chart >
KNTE Price/Volume Stats
| Current price | $7.53 | 52-week high | $15.86 |
| Prev. close | $7.30 | 52-week low | $5.17 |
| Day low | $7.25 | Volume | 149,987 |
| Day high | $7.79 | Avg. volume | 108,479 |
| 50-day MA | $6.70 | Dividend yield | N/A |
| 200-day MA | $9.83 | Market Cap | 332.56M |
Kinnate Biopharma (KNTE) Company Bio
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.
Latest KNTE News From Around the Web
Below are the latest news stories about KINNATE BIOPHARMA INC that investors may wish to consider to help them evaluate KNTE as an investment opportunity.
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers SymposiumSAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company’s investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences. KIN-3248 is an irreversible, small molecule pan-FGFR inhibitor des |
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Kinnate Biopharma dips after Stifel downgrade (NASDAQ:KNTE)Kinnate Biopharma (KNTE) shares fell 15% in Thursday''s trading after Stifel Nicolaus downgraded the stock from Buy to Hold.Analyst Benjamin Burnett raised questions over the the… |
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate UpdatesSAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the quarter ended September 30, 2022, and recent corporate updates. |
Kinnate Biopharma GAAP EPS of -$0.70 misses by $0.10 (NASDAQ:KNTE)Kinnate Biopharma press release (KNTE): Q3 GAAP EPS of -$0.70 misses by $0.10.Cash and Cash Equivalents and Investments Position: As of September 30, 2022, the total of cash and… |
KNTE Price Returns
| 1-mo | 23.44% |
| 3-mo | -11.31% |
| 6-mo | -40.19% |
| 1-year | -31.42% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 23.44% |
| 2022 | -65.58% |
| 2021 | -55.46% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...